



Consolidated Financial Results
for the Three Months Ended March 31, 2026
[Japanese GAAP]

May 14, 2026

Company name:	FINDEX Inc.	
Listing:	Tokyo Stock Exchange	
Securities code:	3649	
URL:	https://findex.co.jp/en/index.html	
Representative:	Teruo Aibara, President & CEO	
Inquiries:	Takahiro Yazawa, Director & CFO	
Telephone:	+81-3-6271-8958	
Scheduled date to commence dividend payment:		N/A
Preparation of supplementary material on financial results:		Yes
Holding of financial results briefing:		No

1. Consolidated Financial Results for the Three Months ended March 31, 2026
(From January 1, 2026 to March 31, 2026)

**Figures are rounded down to the nearest million yen, except share and per share data*

**“%” indicates year-on-year changes from the previous corresponding period*

(1) Consolidated Operating Results

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	JPY MM	%	JPY MM	%	JPY MM	%	JPY MM	%
Three months ended								
March 31, 2026	1,989	2.0	803	(2.4)	825	(1.9)	563	(2.6)
March 31, 2025	1,951	(8.1)	823	(4.5)	841	(2.8)	578	(10.1)

(Note) Comprehensive income: Q1 FY2026: 554 million yen [(2.7)%], Q1 FY2025: 569 million yen [(12.6)%]

	Basic earnings per share	Diluted earnings per share
	JPY	JPY
Three months ended		
March 31, 2026	23.07	-
March 31, 2025	22.53	-

(Note) No statement is indicated above for the number of diluted earnings per share because there were no issuable shares.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	JPY MM	JPY MM	%	JPY
As of				
March 31, 2026	6,956	5,678	81.1	231.27
December 31, 2025	6,807	5,467	79.9	222.91

(Ref.) Equity: As of Q1 FY2026: 5,645 million yen, as of FY2025: 5,440 million yen

2. Cash Dividends

	Annual dividends per share				
	1st quarter	2nd quarter	3rd quarter	Year-end	Total
	JPY	JPY	JPY	JPY	JPY
Year ended December 31, 2025	-	8.00	-	14.00	22.00
Year ending December 31, 2026	-				
Year ending December 31, 2026 (Forecast)		13.00	-	14.00	27.00

(Note) Revisions to the forecast for dividends announced most recently: None

3. Consolidated Financial Forecasts for the Fiscal Year ending December 31, 2026 (From January 1, 2026 to December 31, 2026)

* Figures are rounded down to the nearest million yen, except share and per share data

* “%” indicates year-on-year changes from the previous corresponding period

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	JPY MM	%	JPY MM	%	JPY MM	%	JPY MM	%	JPY
Fiscal year ending December 31, 2026	6,209	1.6	1,829	2.2	1,889	2.6	1,302	3.6	53.34

(Note) Revisions to the most recently announced financial forecast: None

*Notes:

(1) Changes in Significant Subsidiaries during the Current Quarter: None

Newly included companies: None, Newly excluded companies: None

(2) Application of Specific Accounting for Preparing the Quarterly Consolidated Financial Statements: None

(3) Changes in Accounting Policies, Changes in Accounting Estimates, and Restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies other than (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of Shares Outstanding (Common Shares)

	As of March 31, 2026	As of December 31, 2025
Number of shares outstanding at the end of the period (treasury shares included)	26,608,800	26,608,800
Number of treasury shares at the end of the period	2,199,665	2,200,265
	Three months ended March 31, 2026	Three months ended March 31, 2025
Average number of outstanding shares during the period	24,408,989	25,662,649

(Note) The number of treasury shares at the end of the period includes our shares held by Custody Bank of Japan, Ltd. (Trust Account E) (131,600 shares for Q1 FY2026, 132,200 shares for FY2025). Our shares held by Custody Bank of Japan, Ltd. (Trust Account) are included in the treasury share deducted in the calculation of the average number of shares during the period (131,746 shares for Q1 FY2026, 138,076 shares for Q1 FY2025).

* This quarterly financial results report is not subject to quarterly review by a certified public accountant or an audit firm.

* Explanation on appropriate use of performance forecasts and other special notes:

The performance forecasts described in this report are based on information currently available to the Group and on certain assumptions and estimates deemed reasonable by the Group. The Group makes no assurance that such forecasts will prove to be accurate. Actual results may differ significantly from these forecasts due to various factors.

Attached Material

Index

1. Qualitative Information on Quarterly Consolidated Financial Results.....	2
(1) Explanation on Operating Results.....	2
(2) Explanation on the Financial Position.....	5
(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements.....	5
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto.....	6
(1) Quarterly Consolidated Balance Sheet	6
(2) Quarterly Consolidated Statements of Income and Comprehensive Income	7
Quarterly Consolidated Statement of Income, Cumulative.....	7
Quarterly Consolidated Statement of Comprehensive Income, Cumulative	8
(3) Notes to the Quarterly Consolidated Financial Statements.....	9
Notes on Segment Information, etc.	9
Notes on Significant Changes in Shareholders' Equity.....	9
Notes on Going Concern Assumption.....	9
Notes on Quarterly Consolidated Statements of Cash Flows.....	9
Additional Information.....	10
3. Supplementary Information.....	11

1. Qualitative Information on Quarterly Consolidated Financial Results

(1) Explanation on Operating Results

The Group believes that, in order to realize its corporate philosophy of “enriching society through valuable technology creation,” it is essential to promptly develop and provide high-quality solutions that meet the needs of medical settings and society at large.

Based on the “exploration of new ideas and technologies,” the Group promotes research and development that enables employees to experience the joy of creating products, while providing products that exceed customer expectations and contribute to the advancement of society. Through these continuous efforts, the Group aims to achieve sustainable growth and thereby enhance corporate value and shareholder value over the medium to long term. This is the Group’s fundamental management policy.

In addition, the Group continues to promote initiatives aimed at improving employee health and enhancing workplace engagement. In March 2026, the Group once again obtained certification as a “KENKO Investment for Health.”

The consolidated financial results for the three months ended March 31, 2026 are as follows.

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026	Change (amount)	Change (%)	Progress rate (%)
Net sales	1,951,584	1,989,888	38,304	2.0%	32.0%
Operating profit	823,532	803,702	(19,829)	(2.4%)	43.9%
Ordinary profit	841,158	825,116	(16,042)	(1.9%)	43.7%
Profit attributable to owners of parent	578,294	563,130	(15,164)	(2.6%)	43.3%

In the first three months of the current consolidated fiscal year ending December 31, 2026 (January 1, 2026 to March 31, 2026), net sales were ¥1,989,888 thousand (up 2.0% YoY), operating profit was ¥803,702 thousand (down 2.4% YoY), ordinary profit was ¥825,116 thousand (down 1.9% YoY), and profit attributable to owners of parent was ¥563,130 thousand (down 2.6% YoY). The progress rates against the full-year performance forecast are 32.0% for net sales, 43.9% for operating profit, 43.7% for ordinary profit, and 43.3% for profit attributable to owners of the parent.

In the first quarter of the current consolidated fiscal year, the Group recorded an increase in net sales, reflecting steady sales in the Medical Business segment and the recording of sales from the medical data platform business in the Health Tech Business segment. In terms of profit, personnel expenses increased due to strategic hiring, mainly in the Health Tech Business segment, as part of efforts to strengthen organic growth outlined in the “Growth Strategy and Shareholder Return Policy”. As a result, each profit item declined year on year; however, this was in line with the Group’s plan to expand its future earnings base.

Consolidated results by segment for the first three months of the current fiscal year are as follows.

《Medical Business Segment》

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026	Change (amount)	Change (%)
Net sales	1,741,883	1,822,281	80,398	4.6%
Operating profit	740,069	778,240	38,170	5.2%

Mainstay products in the Medical Business segment include the data management software *Claiο*, the progress note system *C-Note*, and the document management software *DocuMaker*. In addition to traditional on-premises products, the Group has also been expanding its cloud-based service offerings in recent years, including the patient guidance application *PiCls Medical Avenue* and the electronic tracing report service *PiCls AAdE-Report*, which are designed to promote hospital DX.

In the first quarter of the current consolidated fiscal year, the Group completed 21 projects for hospitals and 24 projects for clinics, including new installations, add-ons, and system updates. As a result, the segment recorded net sales of ¥1,822,281 thousand (up 4.6% YoY), and operating profit of ¥778,240 thousand (up 5.2% YoY). The primary drivers for the increase in both sales and profit were steady demand for system updates and

the acquisition of new users. Furthermore, profitability increased due to a lower cost-of-sales ratio and higher gross margins, driven by the expansion of maintenance and cloud services, an increased sales mix of high-value-added products, and a reduction in procurement costs.

The *PiClS* series, a cloud service that assists large hospitals in improving profitability and reducing costs, as well as *CocktailAI*, a medical document generation solution leveraging generative AI from Fitting Cloud Inc., a subsidiary of the Company, continued to receive high acclaim, and the number of installations increased steadily in the first quarter of the current consolidated fiscal year. In addition, the number of users of *DocuMaker Cloud*, a cloud-based documentation service for clinics, also increased, with conversions from free to paid plans continuing to accumulate steadily. In the digital domain, the Group strengthened information dissemination through its official X account, formerly Twitter, and newly launched an Instagram account, thereby enhancing its approach to clinics as potential customers.

Despite the challenging management environment many hospitals currently face, the Group's products remain indispensable systems and services for medical professionals and have maintained a high retention rate of over 98.0% in recent years. The Group's clinic clients are primarily in medical specialties with stable business operations, while its hospital clients are centered on acute care hospitals. As a result, the Group has maintained solid business operations supported by a highly stable customer base.

《Public Sector Business Segment》

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026	Change (amount)	Change (%)
Net sales	189,802	103,038	(86,763)	(45.7%)
Operating profit	133,119	32,021	(101,097)	(75.9%)

The flagship product of the Public Business segment is *DocuMaker Office*, a cloud-based DX solution. For public institutions and local governments, the segment provides high-performance electronic approval and official document management systems featuring superior UI/UX. For the administrative departments of medical institutions, it offers administrative document creation and management systems and electronic approval systems equipped with workflow automation functions, with strengths in supporting hospital function evaluations.

In the first quarter of the current consolidated fiscal year, 9 packaged solutions for local governments, and 1 packaged solution for hospital went into operation. As a result, the segment recorded net sales of ¥103,038 thousand (down 45.7% YoY) and operating profit of ¥32,021 thousand (down 75.9% YoY). Although stock revenue exceeded the level of the same period of the previous fiscal year, net sales and profit decreased due to the absence of the revenue contribution from a large-scale project recorded in the same period of the previous fiscal year.

For packaged solutions for local governments, many proposal processes were conducted earlier than usual, and the Group received orders for 3 direct sales projects and 2 agency sales projects in the first quarter of the current consolidated fiscal year. Through implementation work that accurately reflects on-site needs, all projects scheduled to go into operation in April achieved stable operations, and implementation work for other projects is also progressing steadily. The Group is also actively pursuing sales activities, with multiple negotiations underway for new projects scheduled to go into operation in the current fiscal year and the next fiscal year. In addition, projects for packaged solutions for medical institutions are progressing steadily toward implementation, and new inquiries are also increasing.

Since the launch of the service, a cumulative total of 64 packaged solutions for local governments and 14 packaged solutions for medical institutions have gone into operation, with the total number of users reaching approximately 48,000. There have been no cancellations since the launch of the service, and the Group has continued to steadily build its customer base, as it did in the previous fiscal year. As the Group's proposal capabilities and product quality have been highly regarded, the number of projects is expected to continue increasing steadily, and the scale of the business is also expected to expand further.

《Health Tech Business Segment》

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026	Change (amount)	Change (%)
Net sales	19,898	64,568	44,670	224.5%
Operating loss	(49,656)	(6,559)	43,096	-

The Health Tech Business segment consists of the medical device-related business, which is centered on the development and sale of *GAP*^{*1}, a gaze analyzing perimeter, and *GAP-screener*^{*2}, as well as the medical data platform business, which promotes the utilization of medical data.

In the first quarter of the current consolidated fiscal year, sales volume of gaze analyzing perimeter was 1 unit. In addition, as net sales from the medical data platform business have been included in this segment from the first quarter of the current consolidated fiscal year, the segment recorded net sales of ¥64,568 thousand (up 224.5% YoY), and an operating loss of ¥6,559 thousand, compared with an operating loss of ¥49,656 thousand in the same period of the previous fiscal year. Net sales increased due to consulting services and commissioned development in the medical data platform business, while expenses related to upfront investments were also incurred, including development costs for an MCI, or mild cognitive impairment, testing device for which preparations for medical device application are underway, as well as personnel expenses associated with the expansion of the AI analytics team that analyzes medical vital data.

GAP and *GAP-screener* are affordable, groundbreaking wearable devices that enhance availability by measuring patients' visual fields with a completely different approach to that of conventional examination methods. These can also contribute to the early detection of retinal diseases, such as glaucoma and other conditions that lack obvious symptoms in the early stages. Unlike conventional visual field examinations, these devices do not require the use of a dark room, thus shortening the examination time and alleviating the burden on patients. Moreover, by promoting the use of *GAP-screener* at facilities that conduct medical exams and health checkups, early-stage retinal disease patient data can be shared with R&D centers in Japan and overseas with the potential for it to contribute to the innovation of technology and solutions in numerous fields, including pharmaceuticals and life insurance.

GAP has been distributed to ophthalmologic hospitals and clinics nationwide through various medical equipment distributors, while *GAP-screener* is being sold to health check-up facilities. For the domestic market, the Group has begun offering maintenance plans aimed at enhancing convenience and support services, and has introduced incentive plans for its sales distributors, thereby strengthening its sales promotion structure. The number of overseas sales distributors has expanded to 72, including those in Asia and South America. In addition, as the Group has been developing a shipment structure for Argentina, Chile, and Mexico, it expects to continue expanding sales in stages going forward.

In the medical data platform business, the Group is working to provide an environment in which clinical data held by medical institutions is securely anonymized or pseudonymized, collected, and integrated, and can then be utilized by medical research institutions and companies for R&D, drug discovery support, governmental policy planning, and other purposes. Through the utilization of high-value-added electronic medical record data that reflects real-world clinical practice, the Group aims to contribute to the advancement and greater efficiency of R&D in the medical field. In addition, to promote the secure utilization of medical data under the Next Generation Medical Infrastructure Act^{*3}, the Group is developing the necessary framework toward the launch of operations for an environment, where users can safely utilize data.

(Note 1) Gaze Analyzing Perimeter, *GAP* (Notification No. of medical device manufacturing and sales 38B2X10003000002)

(Note 2) Gaze Analyzing Perimeter, *GAP-screener* (Notification No. of medical device manufacturing and sales 38B2X10003000003)

(Note 3) Next Generation Medical Infrastructure Act: The official name is the “Act on Anonymously Processed Medical Information and Pseudonymized Medical Information for the Purpose of Research and Development in the Medical Field”. This law promotes the utilization of medical data by allowing secondary use, such as for new drug development, after processing personal information, including clinical and physical data, so that individuals cannot be identified.

(2) Explanation on the Financial Position
Status of Assets, Liabilities, and Net assets

(JPY in thousands)

	As of December 31, 2025	As of March 31, 2026	Change in Amount
Assets	6,807,858	6,956,963	149,105
Liabilities	1,340,763	1,278,420	(62,342)
Net Assets	5,467,095	5,678,543	211,448

In the first quarter of the current consolidated fiscal year, total assets stood at ¥6,956,963 thousand, up ¥149,105 thousand from the end of the previous fiscal year. This was mainly attributable to a ¥109,656 thousand increase in current assets, primarily due to a ¥445,326 thousand increase in notes and accounts receivable–trade and contract assets.

Liabilities stood at ¥1,278,420 thousand, down ¥62,342 thousand from the end of the previous fiscal year. This was mainly attributable to a decrease of ¥62,984 thousand in current liabilities, primarily due to a decrease of ¥44,501 thousand in income taxes payable.

Net assets stood at ¥5,678,543 thousand, up ¥211,448 thousand from the end of the previous fiscal year. The increase was mainly attributable to a ¥220,023 thousand rise in shareholders' equity, driven primarily by an increase in retained earnings.

(3) Explanation on Consolidated Financial Forecasts and Other Forward-looking Statements

There are no changes at this time to the consolidated financial results forecasts for the fiscal year ending December 31, 2026, announced in the financial results released on February 12, 2026. If any revisions to the forecasts become necessary, the Group will promptly disclose them.

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Quarterly Consolidated Balance Sheet

(JPY in thousands)

	As of December 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and deposits	1,678,886	1,408,753
Notes and accounts receivable - trade, and contract assets	1,793,102	2,238,429
Merchandise and finished goods	164,166	104,448
Work in process	7,232	4,369
Raw materials and supplies	19,964	19,084
Other	80,320	78,242
Total current assets	3,743,671	3,853,327
Non-current assets		
Property, plant and equipment	85,981	83,908
Intangible assets		
Software	299,227	306,854
Other	344	344
Total intangible assets	299,571	307,198
Investments and other assets	2,678,633	2,712,529
Total non-current assets	3,064,186	3,103,636
Total assets	6,807,858	6,956,963
Liabilities		
Current liabilities		
Accounts payable - trade	36,090	41,377
Accounts payable - other	127,991	140,931
Income taxes payable	345,067	300,565
Other	517,400	480,690
Total current liabilities	1,026,550	963,565
Non-current liabilities		
Provision for share awards	314,130	314,785
Other	83	69
Total non-current liabilities	314,213	314,855
Total liabilities	1,340,763	1,278,420
Net assets		
Shareholders' equity		
Share capital	254,259	254,259
Capital surplus	225,785	225,785
Retained earnings	6,755,228	6,974,789
Treasury shares	(1,752,311)	(1,751,848)
Total shareholders' equity	5,482,962	5,702,985
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(42,005)	(57,865)
Total accumulated other comprehensive income	(42,005)	(57,865)
Non-controlling interests	26,138	33,423
Total net assets	5,467,095	5,678,543
Total liabilities and net assets	6,807,858	6,956,963

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
(Quarterly Consolidated Statement of Income, Cumulative)

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026
Net sales	1,951,584	1,989,888
Cost of sales	604,432	580,820
Gross profit	1,347,151	1,409,068
Selling, general and administrative expenses	523,619	605,365
Operating profit	823,532	803,702
Non-operating income		
Interest income	12,296	12,527
Foreign exchange gains	—	8,499
Subsidy income	2,029	—
Royalty income	1,660	—
Other	1,745	387
Total non-operating income	17,733	21,414
Non-operating expenses		
Commission for purchase of treasury shares	106	—
Total non-operating expenses	106	—
Ordinary profit	841,158	825,116
Profit before income taxes	841,158	825,116
Income taxes - current	254,446	258,051
Income taxes - deferred	3,347	(3,350)
Total income taxes	257,794	254,701
Profit	583,364	570,415
Profit attributable to non-controlling interests	5,069	7,284
Profit attributable to owners of parent	578,294	563,130

(Quarterly Consolidated Statement of Comprehensive Income, Cumulative)

(JPY in Thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026
Profit	583,364	570,415
Other comprehensive income		
Valuation difference on available-for-sale securities	(13,622)	(15,859)
Total other comprehensive income	(13,622)	(15,859)
Comprehensive income	569,742	554,555
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	564,672	547,270
Comprehensive income attributable to non-controlling interests	5,069	7,284

(3) Notes to the Quarterly Consolidated Financial Statements

(Notes on Segment Information, etc.)

[Segment Information]

Sales and Profit or Loss by Reportable Segment

Three Months ended March 31, 2025 (From January 1, 2025 to March 31, 2025)

(JPY in thousands)

	Reportable segment				Reported amount for consolidated financial statements (Note)
	Medical Business	Public Sector Business	Health Tech Business	Sub total	
Net sales					
Sales for external customers	1,741,883	189,802	19,898	1,951,584	1,951,584
Internal sales or transfers between segments	-	-	-	-	-
Total net sales	1,741,883	189,802	19,898	1,951,584	1,951,584
Segment profit or loss	740,069	133,119	(49,656)	823,532	823,532

(Note) Aggregated amount of segment income or loss equals amount of operating profit reported for consolidated financial statements.

Three Months ended March 31, 2026 (From January 1, 2026 to March 31, 2026)

(JPY in thousands)

	Reportable segment				Reported amount for consolidated financial statements (Note)
	Medical Business	Public Sector Business	Health Tech Business	Sub total	
Net sales					
Sales for external customers	1,822,281	103,038	64,568	1,989,888	1,989,888
Internal sales or transfers between segments	-	-	-	-	-
Total	1,822,281	103,038	64,568	1,989,888	1,989,888
Segment profit or loss	778,240	32,021	(6,559)	803,702	803,702

(Note) Aggregated amount of segment income or loss equals amount of operating profit reported for consolidated financial statements.

(Notes on Significant Changes in Shareholders' Equity): N/A

(Notes on Going Concern Assumption): N/A

(Notes on Quarterly Consolidated Statements of Cash Flows)

The quarterly consolidated statement of cash flows for the first quarter of the current consolidated fiscal year has not been prepared. Depreciation and amortization of software for sale, related to the first quarter of the consolidated fiscal year, are as follows.

(JPY in thousands)

	Three months ended March 31, 2025	Three months ended March 31, 2026
Depreciation	7,431	8,896
Amortization of Software	65,461	66,427

【Additional Information】

(Accounting Treatment for Employee Stock Ownership Plan, J-ESOP)

At the Board of Directors meeting held on October 29, 2015, the Company resolved to adopt an employee stock ownership plan (referred to as J-ESOP) as an incentive plan to grant Company shares purchased from the market to employees in order to more closely link the Company's share price and earnings with employee compensation and to boost the motivation and morale of employees to improve the share price and earnings by sharing the economic benefits with shareholders.

Accordingly, Trust & Custody Services Bank, Ltd. (trust account E) (now Custody Bank of Japan, Ltd. (trust account E)) acquired 194,200 shares of the Company's stock between November 13, 2015 and November 26, 2015.

Regarding accounting treatment for the J-ESOP, the Company has applied the gross method to record trust assets and liabilities as corporate assets and liabilities on the consolidated balance sheet in accordance with the Practical Solution on Transactions of Delivering the Company's Own Stock to Employees etc. through Trusts (PITF No. 30, March 26, 2015).

The treasury stock held by Custody Bank of Japan, Ltd. (trust account E) is shown as treasury shares in the net assets section of the quarterly consolidated balance sheet. The amount recorded at the end of the previous fiscal year was ¥101,983 thousand and the number of shares was 132,200. The amount recorded at the end of the first quarter of the current consolidated fiscal year was ¥101,520 thousand and the number of shares was 131,600.

3. Supplementary Information

(1) Transition of Significant Financial Key Performance Indicators

(JPY in thousands, except for per share amounts)

	Three months ended March 31, 2025	Three months ended March 31, 2026	Fiscal year ended December 31, 2025
Net sales	1,951,584	1,989,888	6,109,941
Operating profit	823,532	803,702	1,790,029
Ordinary profit	841,158	825,116	1,840,735
Profit	583,364	570,415	1,278,403
Profit or loss attributable to owners of non-controlling interests	5,069	7,284	21,432
Profit attributable to owners of parent	578,294	563,130	1,256,970
Comprehensive income	569,742	554,555	1,250,714
Net assets	5,919,745	5,678,543	5,467,095
Total assets	7,031,796	6,956,963	6,807,858
Net assets per share (yen)	230.84	231.27	222.91
Basic earnings per share (yen)	22.53	23.07	50.07

(2) Production, Order, Sales

1) Actual Result of Production for Q1 FY2026 (Cumulative Amount)

Business segment	Production (JPY in thousands)	YoY (%)
Medical Business	382,863	99.4
Public Sector Business	33,686	109.1
Health Tech Business	33,953	107.7
Total	450,503	100.7

(Note) Figures above is calculated by total manufacturing cost for the current quarter.

2) Order Status for Q1 FY2026 (Cumulative Amount)

Business segment	Order received (JPY in thousands)	YoY (%)	Order backlog (JPY in thousands)	YoY (%)
Medical Business	1,116,977	103.6	1,530,014	146.9
Public Sector Business	5,255	10.8	39,406	89.1
Health Tech Business	30,750	283.3	—	—
Total	1,152,982	101.4	1,569,420	144.2

3) Sales Result for Q1 FY2026 (Cumulative by Product and Service)

Segment, solution, channel	Sales amount (JPY in thousands)	Ratio (%)	YoY (%)
Medical Business			
On-premises software	1,069,232	53.7	107.8
[of via distributors]	[219,871]		
Support	429,910	21.6	101.9
[of via distributors]	[136,573]		
Cloud services	40,070	2.0	-
Consulting	19,650	1.0	35.4
Hardware	141,586	7.1	84.8
Other	121,831	6.1	117.0
Public sector Business			
Cloud services	102,533	5.2	54.2
[of via distributors]	[30,474]		
Other	505	0.0	72.9
Health Tech Business			
Medical devices	15,318	0.8	77.0
Medical data	49,250	2.5	-
Total	1,989,888	100.0	102.0

Note: In order to more appropriately reflect changes in the Group's business structure, product and service categories have been reorganized effective from the first quarter of the current consolidated fiscal year. Year-on-year comparisons are based on figures recalculated in accordance with the revised business segment classification.